Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with troubled regulatory histories. | From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with troubled regulatory histories.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

In an initiative to increase the efficiency of drug manufacturing in the United States, the FDA has

After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing…

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s…

Amid multiple efforts to rein in steep drug costs in the U.S., Colorado has received the all-clear to take matters into its own…

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has…

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the…